《新股消息》清晰醫療(01406.HK)下周一起招股 藥明(02359.HK)持股15.6%
眼科專科醫療機構清晰醫療集團(01406.HK)公布招股詳情,計劃以每股發售價1.6至3元,發行共1.36億股股份,當中90%為國際配售,10%為香港公開發售。每手1,250股,入場費約3,787.78元。
清晰醫療將於下周一(31日)起招股,至2月10日中午截止,預料同日定價,2月18日於主板上市,獨家保薦人為光大證券。
集資所得約44.8%將用於在香港成立兩家新眼科醫療中心;約30.5%用於收購大灣區內1至2家眼科診所、眼科門診部或眼科醫院的股權;約14.7%用作與合作夥伴在中國設立眼科診所;餘下約10%為營運資金及其他一般企業用途。
執行董事兼行政總裁黃棣彰表示,目前於中環及旺角設有兩家眼科中心,過往平均每年增聘數名醫生,現時集團擁有11名執業醫生,集資所得部分會用於在港及大灣區擴張,未來有計劃繼續增聘。
於上市後,私募基金3W Partners將持股約33.16%,藥明康德(02359.HK)持股約15.63%,另外主席胡定旭持股約0.75%。黃棣彰期待在上市後與藥明康德有更緊密合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.